Why These Three Markets — and Why Now
Not every regulated jurisdiction offers the same opportunity for compliant, scalable supply. Australia, Canada and Thailand have each built structured patient access frameworks with robust licensing regimes, defined import and export pathways, and — critically — functioning wholesale and distribution infrastructure. For authorised suppliers, these markets offer something rare: a clear line between regulatory compliance and commercial operation.
Regulatory Maturity and Patient Access
Australia operates one of the most demanding regulatory frameworks globally. The Therapeutic Goods Administration (TGA) and Office of Drug Control (ODC) together govern every stage of the supply chain — from overseas GMP manufacture through to wholesale distribution and clinical dispensing. Schedule 8 classification under the Poisons Standard means each product batch is tracked, tested and reconciled. For producers seeking a credible export destination, Australian approval carries genuine weight.
Canada's Cannabis Act 2018 established a comprehensive federal licensing scheme administered by Health Canada. Canadian licensed producers (LPs) operate under a tiered system covering cultivation, processing and sales — with export provisions that align with international treaty obligations. The maturity of Canada's domestic market has generated a sophisticated understanding of product quality and traceability standards that translates directly to our import requirements in Australia.
Thailand represents the emerging opportunity. Following a series of regulatory reforms from 2022 onwards, Thailand's Food and Drug Administration (FDA) has created defined pathways for medicinal cannabis import, manufacture and distribution. The market remains smaller than Australia or Canada, but patient access programmes are expanding and the regulatory architecture is consolidating quickly. Establishing presence now, with the right local partnerships, positions GLG well ahead of the broader competitive field.
Supply Chain Resilience Across Borders
Operating across three jurisdictions is not simply a growth strategy — it is a risk management position. Single-market supply chains are exposed to individual regulatory shifts, product shortages and seasonal production constraints. GLG's multi-market footprint means that when one supply corridor faces disruption, alternative sources and routes are already licenced, vetted and operational. For wholesale customers in Australia, this translates directly to improved product availability and a more consistent supply schedule.
Our import operations maintain active relationships with GMP-certified producers in multiple jurisdictions. Each relationship is built within the applicable regulatory framework, with batch testing, chain-of-custody documentation and ODC permit compliance embedded at every stage. No shortcuts, regardless of which market the product originates from.
For Overseas Producers — the Right Entry Point
Australia is an attractive but technically demanding export destination. The ODC import permit requirement, TGA registration or Therapeutic Goods Order compliance, GMP certification and NSW Wholesale Poisons Licence obligations together create a barrier that favours producers with strong regulatory track records. GLG acts as the authorised importer and wholesaler — meaning international producers can access the Australian market without needing to navigate the full local licensing stack themselves. We hold the permits, manage the compliance obligations, and provide the distribution infrastructure. Producers bring the product quality and the documentation to match.
For producers looking to enter the Canadian market, our established supply relationships and familiarity with Health Canada's import and export framework provide a useful foundation for structured introductions and commercial arrangements.
The Single Standard — Regardless of Jurisdiction
GLG applies one quality and compliance standard across all three markets. GMP-sourced product only. Full batch documentation. NATA-equivalent laboratory testing. Complete chain-of-custody records from site of manufacture to point of delivery. The applicable local regulatory requirements set the floor — our internal standard sets the ceiling. Whether a consignment is cleared through Sydney, Toronto or Bangkok, it meets the same documentary and quality requirements we apply to every shipment.
This approach protects our licence holders, protects our partners, and — most importantly — protects the integrity of the supply chain that authorised healthcare providers and their patients depend on. Our compliance framework documentation is available to verified partners on request.